Efinaconazole

Drug Profile

Efinaconazole

Alternative Names: Clenafin; IDP-108; Jublia; KP-103

Latest Information Update: 27 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kaken Pharmaceutical
  • Developer Kaken Pharmaceutical; Valeant Pharmaceuticals International
  • Class Antifungals; Piperidines; Small molecules; Triazoles
  • Mechanism of Action 14-alpha demethylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Onychomycosis

Most Recent Events

  • 22 Jun 2016 Valeant Pharmaceuticals International plans a phase IV trial for Onychomycosis (In children, In adolescents) in USA (Topical, Liquid) (NCT02812771)
  • 09 Jun 2014 Registered for Onychomycosis in USA (Topical)
  • 03 Oct 2013 Registered for Onychomycosis in Canada (Topical) - First global approval
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top